Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Highly Accessed Short report

MiR-34b is associated with clinical outcome in triple-negative breast cancer patients

Marek Svoboda1*, Jiri Sana1, Martina Redova1, Jiri Navratil1, Marketa Palacova1, Pavel Fabian2, Ondrej Slaby1 and Rostislav Vyzula1

Author affiliations

1 Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno 656 53, the Czech Republic

2 Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer, Institute, Zluty kopec 7, Brno 656 53, the Czech Republic

For all author emails, please log on.

Citation and License

Diagnostic Pathology 2012, 7:31  doi:10.1186/1746-1596-7-31

Published: 22 March 2012

Abstract

Background

Breast cancer is the most common malignancy with the highest incidence rates among women worldwide. Triple-negative breast cancer (TNBC) represents the major phenotype of basal-like molecular subtype of breast cancer, characterized by higher incidence in young women and a very poor prognosis. MicroRNAs (miRNAs) are small non-coding RNAs playing significant role in the pathogenesis of many cancers including breast cancer. Therefore, miRNAs are also potential prognostic and/or predictive biomarkers in triple-negative breast cancer patients.

Methods

Thirty-nine TNBC patients with available formalin-fixed paraffin-embedded (FFPE) tissues were enrolled in the study. MiR-34a, miR-34b, and miR-34c were analyzed using qRT-PCR and correlated to clinico-pathological features of TNBC patients.

Results

Expression levels of miR-34b significantly correlate with disease free survival (DFS) (p = 0.0020, log-rank test) and overall survival (OS) (p = 0.0008, log-rank test) of TNBC patients. No other significant associations between miR-34a, miR-34b, and miR-34c with available clinical pathological data were observed.

Conclusions

MiR-34b expression negatively correlates with disease free survival and overall survival in TNBC patients. Thus, miR-34b may present a new promising prognostic biomarker in TNBC patients, but independent validations are necessary.

Keywords:
triple-negative breast cancer; miR-34a; miR-34b; miR-34c; prognosis